A Framingham biotech just became a $1.9B Italian acquisition. Here’s the drug behind it

A Framingham biotech just became a $1.9B Italian acquisition. Here’s the drug behind it

Chiesi Group, an Italian biopharmaceutical giant, has finalized its takeover of Framingham’s KalVista Pharmaceuticals — gaining control of the company’s leading drug, EKTERLY.EKTERLY (sebetralstat) is the first and only oral, on-demand treatment approved for hereditary angioedema attacks — a rare genetic disease that causes sudden, painful episodes of swelling that can become life-threatening depending on where in the body they occur.